Recurrent pregnancy loss in a patient with anti‐ Rh17
Transfusion Medicine · 2024
DOI: 10.1111/tme.13014 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transfusion Medicine, 2024. Verfasst von Bushra Moiz und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan. Hauptthemen laut MEDLINE: Blood Group Antigens, Abortion, Habitual. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
Rh is one of the most important blood group systems in transfusion medicine. The two homologous genes RHD and RHCE are located on chromosome 1p36.11 and encode for RhD and RhCE proteins, respectively. Complex genetic polymorphisms result in a variety of antigenic expression of D, C, E, c, and e. Here, we describe a case of a young female with D−− who developed anti‐Rh17 secondary to blood transfusion and had signs of haemolytic disease of the fetus and fetal death in five consecutive pregnancies. Case Description EDTA‐whole blood samples were collected from the patient, husband and eight siblings for blood grouping, phenotyping, and red cell antibody screening. Extracted DNA was genotyped by SNP‐microarray and massively parallel sequencing (MPS) with targeted blood group exome sequencing. Copy number variation analysis was performed to identify structural variants in the RHD and RHCE . Routine phenotyping showed all family members were D+. The patient's red blood cells were C−E−c−e−, Rh17− and Rh46− and had anti‐Rh17 and anti‐e antibodies. MPS showed the patient carried a wildtype RHD sequence and homozygous for RHCE (1)– D (2–9)– CE (10) hybrid gene predicted to express a D−− phenotype.
Conclusions
Our patient had a rare D−− phenotype and confirmed to have RHCE/RHD hybrid gene with replacement of 2–9 exons of RHCE by RHD sequences. Unfortunately, our patient developed anti‐Rh17 and anti‐e antibodies due to blood transfusion and suffered fetal demise in her very first pregnancy. The adverse outcomes could have been prevented by active prenatal management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.
- Red Cell Reference Laboratory, Clinical Services and Research, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia.
- Research and Development, Clinical Services and Research, Australian Red Cross Lifeblood, Kelvin Grove, Queensland, Australia.
- School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, Queensland, Australia.
- School of Health and Behavioural Sciences, University of the Sunshine Coast, Sippy Downs, Queensland, Australia.
ORCID-Profile: Bushra Moiz, Genghis H Lopez
Zitieren
APA
Moiz, B., Salman, M., Rasheed, S., Qudus, R., Millard, G., Hyland, C. A., Flower, R. L., Wilson, B., Turner, R., Lopez, G. H., & Liew, Y. W. (2024). Recurrent pregnancy loss in a patient with anti‐ Rh17. Transfusion Medicine. https://doi.org/10.1111/tme.13014
Vancouver
Moiz B, Salman M, Rasheed S, Qudus R, Millard G, Hyland CA, et al. Recurrent pregnancy loss in a patient with anti‐ Rh17. Transfusion Medicine. 2024. doi:10.1111/tme.13014
BibTeX
@article{Moiz2024,
author = {Moiz, Bushra and Salman, Muhammed and Rasheed, Seher and Qudus, Ruhul and Millard, Glenda and Hyland, Catherine A and Flower, Robert L and Wilson, Brett and Turner, Robyn and Lopez, Genghis H and Liew, Yew-Wah},
title = {Recurrent pregnancy loss in a patient with anti‐ Rh17},
journal = {Transfusion Medicine},
year = {2024},
doi = {10.1111/tme.13014}
}
EUVIMED